Today's Research: Inovio Pharmaceuticals Inc., Sequenom Inc., Nektar
Therapeutics, and Discovery Laboratories Inc.
LONDON, October 28, 2013
LONDON, October 28, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
The U.S. equity market edged higher on Friday, October 25, 2013. The S&P 500
ended the day at 1,759.77, up 0.44%; the Dow Jones Industrial Average closed
at 15,570.28, up 0.39%; and the NASDAQ Composite finished at 3,943.36, up
0.37%. Shares in the Biotechnology industry ended on a mixed note, even as the
broader market posted gains. The major movers in the industry included Inovio
Pharmaceuticals Inc. (NYSE MKT: INO), Sequenom Inc. (NASDAQ: SQNM), Nektar
Therapeutics (NASDAQ: NKTR), and Discovery Laboratories Inc. (NASDAQ: DSCO).
AAAResearchReports.com has completed their technical analysis on INO, SQNM,
NKTR, and DSCO and these free reports are accessible by registering at:
Shares in Inovio Pharmaceuticals Inc. ended the day 1.01% higher at $2.00,
after oscillating between $1.97 and $2.02 during Friday's session. A total of
1.48 million shares were traded, which is significantly below the daily
average volume of 9.22 million. Inovio Pharmaceuticals Inc.'s stock has surged
38.89% in the previous three months, outperforming the S&P 500, which has
gained 4.03% during the same period. Further, the company's shares are trading
above their 200-day moving average of $1.13. Sign up for free technical
research on INO at:
On Friday, Sequenom Inc.'s stock advanced to close at $2.34, up 0.86% from the
previous day's closing price of $2.32. The company's shares vacillated between
$2.30 and $2.38 during the trading session. A total of 1.80 million shares
were traded, which is below the daily average volume of 3.47 million. The
company's shares have gained 1.30% in the previous three trading sessions,
outperforming the S&P 500, which has gained 0.29% during the same period.
However, Sequenom Inc.'s stock is trading below its 50-day and 200-day moving
averages of $2.75 and $3.74, respectively. Be sure to read our latest
technical research on SQNM by registering at:
Nektar Therapeutics' stock plummeted by 3.08% to $10.39, after oscillating
between $10.27 and $10.75 during Friday's trading session. A total of 0.67
million shares were traded, which is below the daily average volume of 1.36
million. The company's stock has fallen by 0.95% in the previous three trading
sessions, underperforming the S&P 500, which has gained 0.29% during the same
period. Moreover, Nektar Therapeutics' stock is trading below its 50-day and
200-day moving averages of $11.73 and $10.69, respectively. Sign up and read
the complimentary report on NKTR at:
Shares in Discovery Laboratories Inc. fell by 0.85% on Friday, even as the
broader market posted gains. The company's shares closed the day at $2.32,
after trading between $2.27 and $2.35. A total of 0.41 million shares were
traded, which is below the daily average volume of 0.68 million. Despite
Friday's losses, the company's shares have surged 16.58% in the last one month
and 42.33% in the previous three months, outperforming the S&P 500, which has
advanced 4.02% and 4.03% during the respective periods. Furthermore, Discovery
Laboratories Inc.'s stock is trading above its 50-day and 200-day moving
averages of $2.04 and $1.98, respectively. The free report on DSCO can be
downloaded by signing up now at:
1.This is not company news. We are an independent source and our views do
not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
only human and are prone to make mistakes. If you notice any errors or
omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
increase awareness for mentioned companies to our subscriber base and the
4.If you wish to have your company covered in more detail by our team, or
wish to learn more about our services, please contact us at
5.For any urgent concerns or inquiries, please contact us at
6.Are you a public company? Would you like to see similar coverage on your
company? Send us a full investors' package to
research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
SOURCE AAA Research Reports
Contact: Phone #: + 1 (646) 396-9126, Contact Name: Peter F. Jones, Email ID:
Press spacebar to pause and continue. Press esc to stop.